Statement From The ESC On The Branded vs. Generic Drug Debate - Cheap drugs will help the delivery of health care in Europe
Says Professor Martin,"the action of most modern therapeutics for cardiovascular diseases entails the interaction between a defined molecular species and a receptor or enzyme. As long as appropriate equivalence studies have been performed under the guidance of regulatory authorities, there should be no reason why the manufacture or presentation of a molecule should effect its action. Cheap drugs will help the delivery of health care in Europe."
The European Society of Cardiology (ESC):
The ESC represents nearly 53,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
The ESC achieves this through a variety of scientific and educational activities including the coordination of: clinical practice guidelines, education courses and initiatives, pan-European surveys on specific disease areas and the ESC Annual Congress, the largest medical meeting in Europe. The ESC also works closely with the European Commission and WHO to improve health policy in the EU.
The ESC comprises 3 Councils, 5 Associations, 19 Working Groups, 50 National Cardiac Societies and an ESC Fellowship Community (Fellow, FESC; Nurse Fellow, NFESC). For more information on ESC Initiatives, Congresses and Constituent Bodies see www.escardio.org.
European Society of Cardiology, The European Heart House 2035 Route des Colles, B.P. 179 - Les Templiers, Sophia Antipolis F-06903 France
Be the first to comment on this!
Personal Subscriber? Sign In
Note: Please enter a display name. Your email address will not be publically displayed